Screener
Kestra Medical Technologies KMTS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Kestra Medical Technologies in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Kestra Medical Technologies’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 5:16 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001193125-26-303397
| Line item | Year Ended April 30, 2026 | Year Ended April 30, 2025 |
|---|---|---|
| Deemed dividend for payments to third party on behalf of shareholder | (323) | (1,654) |
| Proceeds from stock option exercises | 593 | - |
| Net cash provided by financing activities | 147,095 | 330,262 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (137,885) | 229,346 |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 237,929 | 8,583 |
| End of period | $100,044 | $237,929 |
| Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets |
Item 16. Form 10-K Summary.
FAQ
- What is Kestra Medical Technologies's net change in cash?
- Kestra Medical Technologies (KMTS) reported net change in cash of -$191.61M in Q1 2026.
- How has Kestra Medical Technologies's net change in cash changed year-over-year?
- Kestra Medical Technologies's net change in cash decreased by 204.6% year-over-year, from $183.24M to -$191.61M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Kestra Medical Technologies's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude